29th August 2021, Sunday

14:00-15:30 (London); 9:00-10:30 (New York); 21:00-22:30 (Beijing)

Zooming info:

https://swanseauniversity.zoom.us/j/8266570519?pwd=aXdrN1pOUFhqSFlSYlFkQjVvNDRHQT09 

Meeting ID: 826 657 0519
Passcode: 718288
Join by SIP: 8266570519@zoomcrc.com
Join by H.323: 162.255.37.11 (US West)

Opening Remarks and Introduction (5 minutes) 

Moderator: Prof. Bin Li
Institute of Orthopaedics, Soochow University, China

Musculoskeletal tissue repair: the role of mesenchymal stem cells and hedgehog signaling (20 minutes )

Prof. Ling Qin
University of Pennsylvania, USA

BMP2 gene- and cell-activated biomaterial scaffold for bone tissue engineering (20 minutes)

Prof. Bing Wang
University of Pittsburgh School of Medicine, USA

Clinical translation of regenerative medicine -- a “three-step” translational strategy in GMU (20 minutes) 

Prof. Zhiyong Zhang
Guangzhou Medical University, China

Discussion + Q&A (30 minutes): Panelists:  

Prof. Gang Li
The Chinese University of Hong Kong, China

Prof. Jaimo Ahn
The University of Michigan, USA 


Prof. James T Triffitt
University of Oxford, UK

Organizing Committee (Alphabetically):
Prof. Xu Cao
Department of Orthopaedics, Johns Hopkins University, USA

Prof. Xiaodong Guo
Department of Orthopaedics, Wuhan Union Hospital, China

Prof. Bin Li
Institute of Orthopaedics, Soochow University, China

Prof. Zengwu Shao
Department of Orthopaedics, Wuhan Union Hospital, China

Prof. Qian Wang
University of South Carolina, USA

Dr. Zhidao Xia
Swansea University Medical School, Swansea, UK

Prof. Weihua Xu
Department of Orthopaedics, Wuhan Union Hospital, China

Dr. Ling Qin is an Associate Professor of Orthopaedic Surgery and Co-Director of PCMD Histology Core at the University of Pennsylvania. She is also an Associate Editor of the  Journal of Orthopaedic Translation and a member of the Editorial Board of the Journal of Bone and Mineral Research. She became ASBMR fellow in 2018 and Fellow of International Orthopaedic Research (FIOR) in 2019. She is currently a standing member of the NIH SBDD (Skeletal Biology Development & Disease) study section. To date, she has published more than 90 peer-reviewed research articles, reviewers, and book chapters in journals such as Sci Transl Med, J Clin Invest, PNAS, Elife, JBMR, Arthritis Rheumatol, Nature etc. The overall goal of her research is to combine studies on fundamental mechanisms of skeletal cell function with translational medicine approaches to treat skeletal diseases. Her group uses a combination of molecular, biochemical, imaging techniques, and animal models to investigate the molecular mechanisms by which hormones and growth factors regulate bone metabolism and skeletal development under normal and pathological conditions. In the past decade, she has made some groundbreaking discoveries that greatly advance our understanding of molecular regulation of bone and cartilage metabolism, stem cell biology, and skeletal development, and provided promising therapeutic tools for skeletal disorders, such as osteoporosis and osteoarthritis. 

Dr. Bing Wang is an Associate Professor in the Vascular Medicine Institute at the Department of Medicine, University of Pittsburgh School of Medicine. Dr. Wang has been engaging in recombinant adeno-associated viral (r.AAV) vector-mediated gene transfer and associated techniques for the treatment of neuromuscular diseases for many years. He has laid the long-term research groundwork for the pathogenesis and treatment of Duchenne muscular dystrophy (DMD), such as rAAV-mediated mini-dystrophin gene replacement and anti-inflammation via NF-kappaB (NF-kB) inhibition. Recently, he published an International Patent Application for the 2nd generation of DMD gene therapy. His research group has also laid the groundwork for the proposed research by developing gene- and cell-based molecular techniques for in vivo and ex vivo gene transfer as well as biomaterial-mediated gene transfer for the tissue regeneration. Since 2008, Dr. Wang has authored/co-authored 55 peer-reviewed publications, 4 review papers, 6 book chapters, and has published 90 abstracts in national/international conferences. Dr. Wang also participates on the Editorials Boards of several professional journals grant review panels (DOD and NIH). He is currently serving as the Deputy Editor for Molecular Therapy Methods & Clinical Development, an official journal of the American Society of Gene & Cell Therapy (ASGCT). Dr. Wang also served as the Chair of the Muscle Topic Committee for the 2018-2020 term at, the Orthopaedic Research Society.

Prof. Gang Li is a full professor in the Department of Orthopedics and Traumatology, Faculty of Medicine, The Chinese University of Hong Kong. His MBBS at the Fourth Military Medical University, Xian, China (1991) and D. Phil. at the University of Oxford School of Medicine, England, UK (1998). The focuses of his research are on biological mechanisms of distraction osteogenesis, stem cell biology, and cell therapy applications in musculoskeletal tissue engineering.  He has published more than 260 peer-reviewed SCI articles with citations over 12,000 and an H index of 60 (Google Scholar 07-2021); 15 book chapters, edited 3 books on tissue engineering, bone biology, distraction histogenesis and Ilizarov techniques.  He is a council member of the Chinese Orthopaedic Research Society; Chinese ORS Representative to International Combined Orthopaedic Research Societies (ICORS); a Member of the International Committee, of the American Orthopaedic Research Society (ORS); Vice Chairman, of the Branch of Regenerative Biomaterials, Chinese Association of Materials; Member-at-Large (Global position), Tissue Engineering and Regenerative Medicine Society (TERMIS) Asia Pacific (AP); Chairman of ILLRS and ASAMI China Branch.  He is executive associate editor for the Journal of Orthopaedic Translation (IF: 5.19); and editor for Calcified Tissue International, Bone and Joint Research, Bone and Journal of Orthopaedic Research.  He holds honorary or visiting Professorship at many prestigious universities such as Monash University, Australia; South-East University Medical School, China; The Airforce Medical University, China; etc.  His work received serval awards including 1st Class Award in Science Advances, Ministry of Science and Technology, PR China; 1st Class Research Award in Science and Technology, Ministry of Education, China; 2nd Class Award in Medical Science and Technology, China Medical Association. He was is elected as a fellow of the International Combined Orthopaedic Research Societies (FIORS) in 2016 and  a fellow of the American Orthopaedic Research Society (FORS) in 2020.  

Prof. James T. Triffitt PhD is an Emeritus Professor of Bone Metabolism, University of Oxford. He gained his Ph.D. at the University of Liverpool in 1964 for research on vitamin D effects on the skeleton. Thereafter he joined Dr W.F. Neuman, University of Rochester, New York studying the chemical dynamics of bone minerals before returning to the UK as MRC Scientific Staff. He moved to Oxford to join Maureen Owen in 1969 and together set up the MRC Bone Research Laboratory at the Nuffield Orthopaedic Centre. In 1979 he joined Professor Marshall Urist in Los Angeles for a two-year sabbatical working on bone morphogenesis and characterisation of BMP. Further work has concerned the characteristics of the stem cells of bone and the biological factors controlling bone formation and turnover in normal and pathological conditions. Other research includes tissue engineering skeletal tissues and investigating bone development and metabolism in common diseases such as osteoporosis and in rare diseases such as fibrodysplasia ossificans progressiva.

Prof.  Jaimo Ahn MD PhD is a surgeon, educator, scientist, clinical investigator, innovator and Professor / Associate Chairman of Orthopaedic Surgery, and Chief of Orthopaedic Trauma at the University of Michigan.  He maintains a busy academic surgical practice while actively engaged in national / international leadership activities including as lead author of “Injuries” in the Burden of Musculoskeletal Disease in the US, Chair of the Evidence Committee of the Orthopaedic Trauma Association (OTA), Board member of Clinical Orthopaedics & Related Research and American Physician Scientists Association, ad hoc Chair of NIH MOSS SBIR/STTR review and innovation activities including with Clementia (Palovaratene), Radius (Tymlos), Genentech (transgenic mice), and Penn UpStart (Skelegen) and others. His collaborative research has been funded by the AO Foundation, OTA, and NIH and published in NEJM, Lancet, JAMA journals, JCI, Science TM. He received his education / training at Stanford, the University of Pennsylvania (formerly Advisory Dean), HSS/Cornell and the University of Bern.